The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer
Open accessAbstract
BACKGROUND: The aromatase inhibitor letrozole is a more effective treatment for metastatic breast cancer and more effective in the neoadjuvant setting than tamoxifen. We compared letrozole with tamoxifen as adjuvant treatment for steroid-hormone-receptor-positive breast cancer in postmenopausal women. METHODS: The Breast International Group (BIG) 1-98 study is a randomized, phase 3, double-blind trial that compared five years of treatment with various adjuvant endocrine therapy regimens in postmenopausal women with hormone-receptor-positive breast cancer: letrozole, letrozole followed by tamoxifen, tamoxifen, and tamoxifen followed by letrozole. This analysis compares the two groups assigned to receive letrozole initially with the two groups assigned to receive tamoxifen initially; events and follow-up in the sequential-treatment groups were included up to the time that treatments were switched. RESULTS: A total of 8010 women with data that could be assessed were enrolled, 4003 in the letrozole group and 4007 in the tamoxifen group. After a median follow-up of 25.8 months, 351 events had occurred in the letrozole group and 428 events in the tamoxifen group, with five-year disease-free survival estimates of 84.0 percent and 81.4 percent, respectively. As compared with tamoxifen, letrozole significantly reduced the risk of an event ending a period of disease-free survival (hazard ratio, 0.81; 95 percent confidence interval, 0.70 to 0.93; P=0.003), especially the risk of distant recurrence (hazard ratio, 0.73; 95 percent confidence interval, 0.60 to 0.88; P=0.001). Thromboembolism, endometrial cancer, and vaginal bleeding were more common in the tamoxifen group. Women given letrozole had a higher incidence of skeletal and cardiac events and of hypercholesterolemia. CONCLUSIONS: In postmenopausal women with endocrine-responsive breast cancer, adjuvant treatment with letrozole, as compared with tamoxifen, reduced the risk of recurrent disease, especially at distant sites. (ClinicalTrials.gov number, NCT00004205.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,960
Tamoxifen for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,085
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032312 · Cited by 1,795
Research works printed but not linked: 5
- Dowsett M, 1995, Clin Cancer Res, 1, 1511
- Geisler J, 1998, Clin Cancer Res, 4, 2089
- Mantel N, 1966, Cancer Chemother Rep, 50, 163
- 10.2307/2281868 · doi:10.2307/2281868 · Paper page
- 10.1016/S1049-3867(01)00075-5 · doi:10.1016/s1049-3867(01)00075-5
Cited by
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Prevention of Venous Thromboembolism
Geerts, W. H., Pineo, G. F., Heit, J. A., Bergqvist, D., Lassen, M. R., Colwell, C. W., & Ray, J. G. (2004) · Chest · doi:10.1378/chest.126.3_suppl.338s · Cited by 5,895
Prevention of Venous Thromboembolism
Geerts, W. H., Bergqvist, D., Pineo, G. F., Heit, J. A., Samama, C. M., Lassen, M. R., & Colwell, C. W. (2008) · Chest · doi:10.1378/chest.08-0656 · Cited by 3,829
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac244 · Cited by 3,076
Kahn (2012) · doi:10.1378/chest.11-2296 · Cited by 2,693
Dowsett, M., Nielsen, T. O., A'Hern, R., Bartlett, J., Coombes, R. C., Cuzick, J., Ellis, M., Henry, N. L., Hugh, J. C., Lively, T., et al. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr393 · Cited by 1,977
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting
Gialeli, C., Theocharis, A. D., & Karamanos, N. K. (2011) · The FEBS Journal · doi:10.1111/j.1742-4658.2010.07919.x · Cited by 1,607
Smith, I., Procter, M., Gelber, R. D., Guillaume, S., Feyereislova, A., Dowsett, M., Goldhirsch, A., Untch, M., Mariani, G., Baselga, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60028-2 · Cited by 1,507
Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer
Gnant, M., Mlineritsch, B., Schippinger, W., Luschin-Ebengreuth, G., Pöstlberger, S., Menzel, C., Jakesz, R., Seifert, M., Hubalek, M., Bjelic-Radisic, V., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806285 · Cited by 1,025
Coates, A. S., Keshaviah, A., Thürlimann, B., Mouridsen, H., Mauriac, L., Forbes, J. F., Paridaens, R., Castiglione-Gertsch, M., Gelber, R. D., Colleoni, M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8617 · Cited by 910
Hudis, C. A., Barlow, W. E., Costantino, J. P., Gray, R. J., Pritchard, K. I., Chapman, J.-A. W., Sparano, J. A., Hunsberger, S., Enos, R. A., Gelber, R. D., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.3523 · Cited by 864
Mehta, L. S., Watson, K. E., Barac, A., Beckie, T. M., Bittner, V., Cruz-Flores, S., Dent, S., Kondapalli, L., Ky, B., Okwuosa, T., et al. (2018) · Circulation · doi:10.1161/cir.0000000000000556 · Cited by 848
Loi, S., Haibe-Kains, B., Desmedt, C., Lallemand, F., Tutt, A. M., Gillet, C., Ellis, P., Harris, A., Bergh, J., Foekens, J. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.1522 · Cited by 837
Chlebowski, R. T., Blackburn, G. L., Thomson, C. A., Nixon, D. W., Shapiro, A., Hoy, M. K., Goodman, M. T., Giuliano, A. E., Karanja, N., McAndrew, P., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj494 · Cited by 825
Burstein, H. J., Prestrud, A. A., Seidenfeld, J., Anderson, H., Buchholz, T. A., Davidson, N. E., Gelmon, K. E., Giordano, S. H., Hudis, C. A., Malin, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3756 · Cited by 796
Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Moran, M. S., Abraham, J., Abramson, V., Aft, R., Agnese, D., Allison, K. H., Anderson, B., Bailey, J., Burstein, H. J., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.0035 · Cited by 664
Progesterone receptor modulates ERα action in breast cancer
Mohammed, H., Russell, I. A., Stark, R., Rueda, O. M., Hickey, T. E., Tarulli, G. A., Serandour, A. A., Birrell, S. N., Bruna, A., Saadi, A., et al. (2015) · Nature · doi:10.1038/nature14583 · Cited by 659
Johnston, S. R. D., Toi, M., O'Shaughnessy, J., Rastogi, P., Campone, M., Neven, P., Huang, C.-S., Huober, J., Jaliffe, G. G., Cicin, I., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00694-5 · Cited by 599
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen
Goetz, M. P., Knox, S. K., Suman, V. J., Rae, J. M., Safgren, S. L., Ames, M. M., Visscher, D. W., Reynolds, C., Couch, F. J., Lingle, W. L., et al. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9428-0 · Cited by 552
Ellis, M. J., Suman, V. J., Hoog, J., Lin, L., Snider, J., Prat, A., Parker, J. S., Luo, J., DeSchryver, K., Allred, D. C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.6950 · Cited by 551
Cuzick, J., Forbes, J. F., Sestak, I., Cawthorn, S., Hamed, H., Holli, K., & Howell, A. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk049 · Cited by 534
Schroth, W. (2009) · JAMA · doi:10.1001/jama.2009.1420 · Cited by 531
Chia, S., Gradishar, W., Mauriac, L., Bines, J., Amant, F., Federico, M., Fein, L., Romieu, G., Buzdar, A., Robertson, J. F. R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.5822 · Cited by 513
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeac106 · Cited by 507
Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810818 · Cited by 496
Ellis, G. K., Bone, H. G., Chlebowski, R., Paul, D., Spadafora, S., Smith, J., Fan, M., & Jun, S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3832 · Cited by 483
Aapro, M., Abrahamsson, P. A., Body, J. J., Coleman, R. E., Colomer, R., Costa, L., Crinò, L., Dirix, L., Gnant, M., Gralow, J., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm442 · Cited by 457
Suicide and Cardiovascular Death after a Cancer Diagnosis
Fang, F., Fall, K., Mittleman, M. A., Sparén, P., Ye, W., Adami, H.-O., & Valdimarsdóttir, U. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110307 · Cited by 455
Viale, G., Regan, M. M., Maiorano, E., Mastropasqua, M. G., Dell'Orto, P., Rasmussen, B. B., Raffoul, J., Neven, P., Orosz, Z., Braye, S., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.9453 · Cited by 452
Carlson, R. W., Allred, D. C., Anderson, B. O., Burstein, H. J., Carter, W. B., Edge, S. B., Erban, J. K., Farrar, W. B., Goldstein, L. J., Gradishar, W. J., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0012 · Cited by 450
Coleman, R. E., Banks, L. M., Girgis, S. I., Kilburn, L. S., Vrdoljak, E., Fox, J., Cawthorn, S. J., Patel, A., Snowdon, C. F., Hall, E., et al. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70003-7 · Cited by 426
NCCN Task Force Report: Bone Health in Cancer Care
Gralow, J. R., Biermann, J. S., Farooki, A., Fornier, M. N., Gagel, R. F., Kumar, R., Litsas, G., McKay, R., Podoloff, D. A., Srinivas, S., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0215 · Cited by 412
Eastell, R., Adams, J. E., Coleman, R. E., Howell, A., Hannon, R. A., Cuzick, J., Mackey, J. R., Beckmann, M. W., & Clack, G. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.0726 · Cited by 407
Regan, M. M., Neven, P., Giobbie-Hurder, A., Goldhirsch, A., Ejlertsen, B., Mauriac, L., Forbes, J. F., Smith, I., Láng, I., Wardley, A., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70270-4 · Cited by 406
Aromatase, aromatase inhibitors, and breast cancer
Chumsri, S., Howes, T., Bao, T., Sabnis, G., & Brodie, A. (2011) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2011.02.001 · Cited by 401
Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial
van de Velde, C. J., Rea, D., Seynaeve, C., Putter, H., Hasenburg, A., Vannetzel, J.-M., Paridaens, R., Markopoulos, C., Hozumi, Y., Hille, E. T., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62312-4 · Cited by 372
Effects of Age on the Detection and Management of Breast Cancer
McGuire, A., Brown, J., Malone, C., McLaughlin, R., & Kerin, M. (2015) · Cancers · doi:10.3390/cancers7020815 · Cited by 374
Progress in adjuvant chemotherapy for breast cancer: an overview
Anampa, J., Makower, D., & Sparano, J. A. (2015) · BMC Medicine · doi:10.1186/s12916-015-0439-8 · Cited by 373
Cardiotoxicity of anticancer treatments: what the cardiologist needs to know
Ewer, M. S., & Ewer, S. M. (2010) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.121 · Cited by 373
Mamounas, E. P., Jeong, J.-H., Wickerham, D. L., Smith, R. E., Ganz, P. A., Land, S. R., Eisen, A., Fehrenbacher, L., Farrar, W. B., Atkins, J. N., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.0228 · Cited by 341
Viale, G., Giobbie-Hurder, A., Regan, M. M., Coates, A. S., Mastropasqua, M. G., Dell'Orto, P., Maiorano, E., MacGrogan, G., Braye, S. G., Öhlschlegel, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.0829 · Cited by 340
Regan, M. M., Leyland-Jones, B., Bouzyk, M., Pagani, O., Tang, W., Kammler, R., Dell’Orto, P., Biasi, M. O., Thürlimann, B., Lyng, M. B., et al. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs125 · Cited by 339
Selective Estrogen-Receptor Modulators and Antihormonal Resistance in Breast Cancer
Jordan, V. C., & O'Malley, B. W. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.3886 · Cited by 324
CYP2D6 and tamoxifen: DNA matters in breast cancer
Hoskins, J. M., Carey, L. A., & McLeod, H. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2683 · Cited by 322
Brufsky, A., Harker, W. G., Beck, J. T., Carroll, R., Tan-Chiu, E., Seidler, C., Hohneker, J., Lacerna, L., Petrone, S., & Perez, E. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.3744 · Cited by 321
Paridaens, R. J., Dirix, L. Y., Beex, L. V., Nooij, M., Cameron, D. A., Cufer, T., Piccart, M. J., Bogaerts, J., & Therasse, P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4659 · Cited by 319
Cardiac Toxicity in Breast Cancer Survivors: Review of Potential Cardiac Problems
Bird, B. R. J. H., & Swain, S. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1033 · Cited by 307
Targeting SphK1 as a New Strategy against Cancer
Shida, D., Takabe, K., Kapitonov, D., Milstien, S., & Spiegel, S. (2008) · Current Drug Targets · doi:10.2174/138945008785132402 · Cited by 307
Hershman, D. L., Unger, J. M., Greenlee, H., Capodice, J. L., Lew, D. L., Darke, A. K., Kengla, A. T., Melnik, M. K., Jorgensen, C. W., Kreisle, W. H., et al. (2018) · JAMA · doi:10.1001/jama.2018.8907 · Cited by 300
Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer
Davey, M. G., Hynes, S. O., Kerin, M. J., Miller, N., & Lowery, A. J. (2021) · Cancers · doi:10.3390/cancers13174455 · Cited by 298
Jordan, V. C., & Brodie, A. M. H. (2007) · Steroids · doi:10.1016/j.steroids.2006.10.009 · Cited by 296
Cella, D., & Fallowfield, L. J. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9548-1 · Cited by 286
Crew, K. D., Capodice, J. L., Greenlee, H., Brafman, L., Fuentes, D., Awad, D., Yann Tsai, W., & Hershman, D. L. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4708 · Cited by 286
Eidtmann, H., de Boer, R., Bundred, N., Llombart-Cussac, A., Davidson, N., Neven, P., von Minckwitz, G., Miller, J., Schenk, N., & Coleman, R. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq217 · Cited by 281
Møller, S., Jensen, M.-B., Ejlertsen, B., Bjerre, K. D., Larsen, M., Hansen, H. B., Christiansen, P., & Mouridsen, H. T. (2008) · Acta Oncologica · doi:10.1080/02841860802059259 · Cited by 273
Belfiore, A., & Malaguarnera, R. (2011) · Endocrine-Related Cancer · doi:10.1530/erc-11-0074 · Cited by 272
Kaufmann, M., Jonat, W., Hilfrich, J., Eidtmann, H., Gademann, G., Zuna, I., & von Minckwitz, G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8054 · Cited by 267
Estradiol Induces Export of Sphingosine 1-Phosphate from Breast Cancer Cells via ABCC1 and ABCG2
Takabe, K., Kim, R. H., Allegood, J. C., Mitra, P., Ramachandran, S., Nagahashi, M., Harikumar, K. B., Hait, N. C., Milstien, S., & Spiegel, S. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.064162 · Cited by 266
Cancer Therapy–Induced Cardiac Toxicity in Early Breast Cancer: Addressing the Unresolved Issues
Khouri, M. G., Douglas, P. S., Mackey, J. R., Martin, M., Scott, J. M., Scherrer-Crosbie, M., & Jones, L. W. (2012) · Circulation · doi:10.1161/circulationaha.112.100560 · Cited by 255
Goss, P. E., Ingle, J. N., Pritchard, K. I., Ellis, M. J., Sledge, G. W., Budd, G. T., Rabaglio, M., Ansari, R. H., Johnson, D. B., Tozer, R., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.7805 · Cited by 255
Adherence to endocrine therapy for breast cancer
Chlebowski, R. T., & Geller, M. L. (2006) · Oncology · doi:10.1159/000100444 · Cited by 251
Adjuvant hormonal therapy use among insured, low-income women with breast cancer
Kimmick, G., Anderson, R., Camacho, F., Bhosle, M., Hwang, W., & Balkrishnan, R. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.2419 · Cited by 198
Effects of estrogen on breast cancer development: Role of estrogen receptor independent mechanisms
Yue, W., Wang, J., Li, Y., Fan, P., Liu, G., Zhang, N., Conaway, M., Wang, H., Korach, K. S., Bocchinfuso, W., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25207 · Cited by 196
Selective estrogen receptor modulators: an update on recent clinical findings
Shelly, W., Draper, M. W., Krishnan, V., Wong, M., & Jaffe, R. B. (2008) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0b013e31816400d7 · Cited by 193
Calibrating Models in Economic Evaluation: A Seven-Step Approach
Vanni, T., Karnon, J., Madan, J., White, R. G., Edmunds, W. J., Foss, A. M., & Legood, R. (2011) · PharmacoEconomics · doi:10.2165/11584600-000000000-00000 · Cited by 173
Lin, B. C., Suzawa, M., Blind, R. D., Tobias, S. C., Bulun, S. E., Scanlan, T. S., & Ingraham, H. A. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-1622 · Cited by 157
“Thus, activation of GPR30 may underlie the higher risk of endometrium hyperplasia and/or cancer in postmenopausal women observed with chronic OHT treatment, but not with aromatase inhibitor therapy (47, 48).”
Aromatase inhibitors in men: effects and therapeutic options
de Ronde, W., & de Jong, F. H. (2011) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-9-93 · Cited by 155
The Effects of Tamoxifen on Immunity
Behjati, S., & Frank, M. (2009) · Current Medicinal Chemistry · doi:10.2174/092986709788803042 · Cited by 116
Cardiovascular disease in cancer survivors
Okwuosa, T. M., Anzevino, S., & Rao, R. (2017) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2016-134417 · Cited by 97
Gregoriou, O., Bakas, P., Grigoriadis, C., Creatsa, M., Hassiakos, D., & Creatsas, G. (2012) · Fertility and Sterility · doi:10.1016/j.fertnstert.2012.04.005 · Cited by 93
The metabolism, analysis, and targeting of steroid hormones in breast and prostate cancer
Capper, C. P., Rae, J. M., & Auchus, R. J. (2016) · Hormones and Cancer · doi:10.1007/s12672-016-0259-0 · Cited by 89
Garg, A., & Simha, V. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0275 · Cited by 89
Ziller, V., Kyvernitakis, I., Knöll, D., Storch, A., Hars, O., & Hadji, P. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-407 · Cited by 82
Karnon, J., & Vanni, T. (2011) · PharmacoEconomics · doi:10.2165/11584610-000000000-00000 · Cited by 67
Neugut, A. I., Hillyer, G. C., Kushi, L. H., Lamerato, L., Leoce, N., Nathanson, S. D., Ambrosone, C. B., Bovbjerg, D. H., Mandelblatt, J. S., Magai, C., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2066-9 · Cited by 63
Therapeutic uses of aromatase inhibitors in men
de Ronde, W. (2007) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e328121aad2 · Cited by 26
Wempe, M. F., Buchanan, C. M., Buchanan, N. L., Edgar, K. J., Hanley, G. A., Ramsey, M. G., Skotty, J. S., & Rice, P. J. (2007) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.59.6.0006 · Cited by 25
Smith, S. G., Green, S. M. C., Ellison, R., Foy, R., Graham, C. D., Mason, E., French, D. P., Hall, L. H., Wilkes, H., McNaught, E., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-069971 · Cited by 20
Metadata
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-12-29
- Volume
- 353
- Issue
- 26
- Pages
- 2747-2757
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1531964529
- Cited by
- 1,577
- References
- 36
- FWCI
- 52.69
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.